Small Intestinal Bacterial Overgrowth (SIBO): Clinical Presentation and Management

Pathophysiology and Clinical Predisposing Factors

The gastric acid barrier acts as the first line of defense against bacterial proliferation, and when compromised, bacteria can survive passage into the small bowel, according to Praxis Medical Insights 1
The migrating motor complex (MMC) clears debris and bacteria from the small intestine during fasting, and dysfunction causes gut stasis and allows bacterial accumulation, as noted by Praxis Medical Insights 2 and Praxis Medical Insights 1
Diabetes mellitus with autonomic neuropathy disrupts MMC function and intestinal clearance, leading to SIBO, as reported by Praxis Medical Insights 1
Pelvic radiation therapy damages intestinal motility mechanisms, contributing to SIBO, according to Gut 3 and Praxis Medical Insights 1

Bloating and abdominal distention are characteristic symptoms of SIBO, worsening postprandially, as described by Praxis Medical Insights 2 and Praxis Medical Insights 4
The British Society of Gastroenterology recommends testing rather than empirical treatment to establish diagnosis and support antibiotic stewardship, as stated in Gut 3
Glucose or lactulose breath tests are noninvasive alternatives to diagnose SIBO, measuring hydrogen and methane production by bacteria, according to Gut 3

Rifaximin 550 mg twice daily for 1-2 weeks is the most investigated and effective treatment for SIBO, achieving symptom resolution in approximately 60-80% of patients, as reported by Gut 3
The ideal approach treats the underlying disease, eradicates bacterial overgrowth, and addresses nutritional deficiencies, as noted by Praxis Medical Insights 1 and Gut 3
Screening for and replacing fat-soluble vitamins (A, D, E, K) is essential in patients with steatorrhea, as recommended by Praxis Medical Insights 2

Mast cells are the predominant immune cell type activated in SIBO and related functional bowel disorders, with increased release of histamine, tryptase, and prostaglandins from mucosal biopsies, according to the American Gastroenterological Association 5
T lymphocytes (CD3+, CD4+, and CD8+ cells) show increased activation in the intestinal mucosa of patients with bacterial overgrowth and functional bowel disorders, as reported by the European Society of Gastrointestinal Motility 5
The immune response represents low-grade activation of innate and adaptive mucosal immunity confined primarily to the gut wall, as stated by the American Gastroenterological Association 5

SIBO causes excessive fermentation and inflammation in the small intestine, which is localized rather than systemic, according to the Nutrition Society 6

Concurrent inflammatory bowel disease (Crohn's disease or ulcerative colitis) can coexist with SIBO in 30% of CD patients, as reported by the American Gastroenterological Association 7
Chronic pancreatitis is associated with SIBO in up to 92% of patients with pancreatic exocrine insufficiency and may be associated with systemic inflammation, according to the Nutrition Society 6

The absence of monocytosis does not rule out SIBO, and conversely, monocytosis should not be attributed to SIBO alone, as stated by the American Gastroenterological Association 8
Treatment with rifaximin 550 mg twice daily for 1-2 weeks targets the bacterial overgrowth directly and achieves symptom resolution in 60-80% of patients, as reported by the European Society of Gastrointestinal Motility 8

The British Society of Gastroenterology recommends performing diagnostic testing rather than empirical therapy to confirm SIBO and promote antibiotic stewardship. 9
Combined hydrogen‑ and methane‑breath testing (using glucose or lactulose substrates) is more accurate than hydrogen‑only testing and should be used as the initial, non‑invasive diagnostic modality. 9
When breath testing is unavailable, a qualitative small‑bowel aspiration during upper endoscopy can be performed: 100 mL sterile saline is flushed into the duodenum, ≥10 mL is aspirated into a sterile trap, and growth of colonic‑type bacteria on culture is considered a positive result. 9
Empirical antibiotic treatment without prior testing should be avoided, because treatment failure may reflect resistant organisms, absence of SIBO, or co‑existing disorders that mimic SIBO symptoms. 9

Rifaximin 550 mg twice daily for 1–2 weeks is the most effective first‑line regimen, achieving symptom resolution in approximately 60–80 % of patients with confirmed SIBO. 9
Rifaximin’s lack of systemic absorption reduces the risk of developing systemic antibiotic resistance. 9
Rifaximin is the most extensively studied antibiotic for SIBO, with consistent efficacy demonstrated across multiple trials. 9

Doxycycline (standard dosing for 1–2 weeks) is considered an equally effective alternative when rifaximin is unavailable or ineffective. 9
Ciprofloxacin may be used at the lowest effective dose for 1–2 weeks, with monitoring for tendonitis as a safety precaution. 9
Amoxicillin‑clavulanic acid and cefoxitin are also listed as alternative agents with comparable efficacy. 9
Metronidazole shows lower documented efficacy and is therefore not recommended as a first‑line option. 9

In patients with reversible predisposing factors (e.g., temporary immunosuppression), a single antibiotic course is usually sufficient; recurrent disease warrants a cyclical approach with 1–2 week antibiotic courses alternating with antibiotic‑free intervals. 9
Low‑dose, long‑term antibiotic regimens may be employed in selected cases, and short‑course repeats can be used as clinically indicated. 9

Vitamin D deficiency is observed in about 20 % of individuals receiving bile‑acid sequestrants, warranting monitoring and supplementation as needed. 9

Pancreatic exocrine insufficiency (faecal elastase < 500 µg/g) can mimic or coexist with SIBO and should be evaluated when symptoms persist after antimicrobial therapy. 9